دورية أكاديمية
أعرض في EDS

Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

التفاصيل البيبلوغرافية
العنوان: Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.
المؤلفون: Frederick MJ; Department of Head and Neck Surgery, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA. mfrederi@mdanderson.org, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS
المصدر: The American journal of pathology [Am J Pathol] 2011 Feb; Vol. 178 (2), pp. 548-71.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0370502 Publication Model: Print Cited Medium: Internet ISSN: 1525-2191 (Electronic) Linking ISSN: 00029440 NLM ISO Abbreviation: Am J Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011-: New York : Elsevier
Original Publication: Philadelphia [etc.] American Assn. of Pathologists [etc.]
مواضيع طبية MeSH: Signal Transduction*, Carcinoma, Squamous Cell/*metabolism , Head and Neck Neoplasms/*metabolism , Neoplasm Proteins/*metabolism , Phosphoproteins/*metabolism , Proteomics/*methods, Biomarkers, Tumor/metabolism ; Blotting, Western ; Carcinoma, Squamous Cell/enzymology ; Carcinoma, Squamous Cell/pathology ; Cell Line, Tumor ; Cluster Analysis ; Female ; Head and Neck Neoplasms/enzymology ; Head and Neck Neoplasms/pathology ; Humans ; Immunohistochemistry ; Male ; Mucous Membrane/metabolism ; Mucous Membrane/pathology ; Phosphorylation ; Protein Array Analysis ; Protein Kinase C/metabolism ; Reproducibility of Results
مستخلص: Molecular targeted therapy represents a promising new strategy for treating cancers because many small-molecule inhibitors targeting protein kinases have recently become available. Reverse-phase protein microarrays (RPPAs) are a useful platform for identifying dysregulated signaling pathways in tumors and can provide insight into patient-specific differences. In the present study, RPPAs were used to examine 60 protein end points (predominantly phosphoproteins) in matched tumor and nonmalignant biopsy specimens from 23 patients with head and neck squamous cell carcinoma to characterize the cancer phosphoproteome. RPPA identified 18 of 60 analytes globally elevated in tumors versus healthy tissue and 17 of 60 analytes that were decreased. The most significantly elevated analytes in tumor were checkpoint kinase (Chk) 1 serine 345 (S345), Chk 2 S33/35, eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) S65, protein kinase C (PKC) ζ/ι threonine 410/412 (T410/T412), LKB1 S334, inhibitor of kappaB alpha (IκB-α) S32, eukaryotic translation initiation factor 4E (eIF4E) S209, Smad2 S465/67, insulin receptor substrate 1 (IRS-1) S612, mitogen-activated ERK kinase 1/2 (MEK1/2) S217/221, and total PKC ι. To our knowledge, this is the first report of elevated PKC ι in head and neck squamous cell carcinoma that may have significance because PKC ι is an oncogene in several other tumor types, including lung cancer. The feasibility of using RPPA for developing theranostic tests to guide personalized therapy is discussed in the context of these data.
(Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
References: Int J Oncol. 2007 Oct;31(4):875-81. (PMID: 17786320)
Cancer Res. 2005 Oct 1;65(19):8905-11. (PMID: 16204062)
Head Neck. 2005 Feb;27(2):130-7. (PMID: 15641106)
Mol Cell Biol. 2007 Apr;27(7):2572-81. (PMID: 17242188)
Oncogene. 2007 Jan 4;26(1):54-64. (PMID: 16819514)
Head Neck. 2007 Oct;29(10):959-71. (PMID: 17405170)
Cancer. 2002 May 1;94(9):2393-400. (PMID: 12015764)
Neoplasma. 2005;52(4):338-43. (PMID: 16059652)
Clin Cancer Res. 2005 Jun 15;11(12):4338-40. (PMID: 15958615)
Clin Cancer Res. 2007 Apr 1;13(7):1955-60. (PMID: 17404075)
J Clin Oncol. 2007 Jun 1;25(16):2164-70. (PMID: 17538160)
Expert Opin Investig Drugs. 2008 Oct;17(10):1517-31. (PMID: 18808311)
Cancer Lett. 2007 Apr 18;248(2):269-79. (PMID: 16996205)
Cancer Res. 2006 Jun 15;66(12):6296-303. (PMID: 16778206)
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32. (PMID: 10760290)
Oncogene. 2008 Jan 10;27(3):323-31. (PMID: 17621268)
Cancer. 2001 Dec 15;92(12):3037-44. (PMID: 11753981)
Mol Cell Proteomics. 2007 Jul;6(7):1198-214. (PMID: 17317660)
PLoS One. 2007 Feb 21;2(2):e242. (PMID: 17311107)
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. (PMID: 19474385)
Am J Pathol. 2002 Aug;161(2):365-71. (PMID: 12163360)
J Oncol. 2009;2009:981679. (PMID: 20049173)
J Natl Compr Canc Netw. 2008 Aug;6(7):696-706. (PMID: 18691458)
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4029-37. (PMID: 15217935)
Mol Carcinog. 1999 Oct;26(2):119-29. (PMID: 10506755)
Nat Rev Drug Discov. 2003 Apr;2(4):296-313. (PMID: 12669029)
J Biochem. 2003 Jan;133(1):9-16. (PMID: 12761193)
Nature. 2005 Apr 14;434(7035):864-70. (PMID: 15829956)
Neoplasia. 2002 Mar-Apr;4(2):171-80. (PMID: 11896572)
Laryngoscope. 1994 Nov;104(11 Pt 1):1337-47. (PMID: 7968162)
Histol Histopathol. 2008 Oct;23(10):1269-78. (PMID: 18712679)
J Clin Oncol. 2006 Sep 1;24(25):4170-6. (PMID: 16943533)
Curr Oncol Rep. 2003 Mar;5(2):140-6. (PMID: 12583831)
Ann Clin Lab Sci. 2005 Summer;35(3):251-8. (PMID: 16081580)
Oral Oncol. 2009 Apr-May;45(4-5):324-34. (PMID: 18805044)
Cancer Sci. 2008 Aug;99(8):1589-94. (PMID: 18754871)
Expert Opin Biol Ther. 2006 Mar;6(3):231-41. (PMID: 16503733)
Cancer Lett. 2001 Oct 10;171(2):165-72. (PMID: 11520600)
Int J Cancer. 2005 Mar 20;114(2):242-8. (PMID: 15543611)
Curr Biol. 1998 Sep 24;8(19):1069-77. (PMID: 9768361)
Histopathology. 2002 Aug;41(2):144-51. (PMID: 12147092)
Oral Oncol. 2006 Apr;42(4):430-9. (PMID: 16442835)
Genes Dev. 2007 Dec 15;21(24):3214-31. (PMID: 18079171)
J Biol Chem. 2000 Jul 7;275(27):20806-13. (PMID: 10764742)
Biosci Rep. 2005 Feb-Apr;25(1-2):107-25. (PMID: 16222423)
Blood. 1999 Jun 1;93(11):3893-9. (PMID: 10339498)
Oncogene. 2009 Oct 15;28(41):3597-607. (PMID: 19617897)
Oral Oncol. 2005 Feb;41(2):183-99. (PMID: 15695121)
Int J Cancer. 2004 Sep 20;111(5):679-92. (PMID: 15252836)
Pathol Res Pract. 1993 Sep;189(8):862-6. (PMID: 8302707)
Curr Opin Genet Dev. 2008 Feb;18(1):80-6. (PMID: 18343102)
J Proteome Res. 2008 Apr;7(4):1508-17. (PMID: 18257519)
Clin Cancer Res. 2008 Feb 15;14(4):1002-14. (PMID: 18281532)
Mol Cell Biol. 2009 Mar;29(5):1152-62. (PMID: 19114552)
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1057-62. (PMID: 15279793)
Cancer. 1996 Sep 15;78(6):1284-92. (PMID: 8826952)
J Biol Chem. 2005 Oct 14;280(41):34538-47. (PMID: 16105840)
Int J Cancer. 2001 Oct 15;94(2):153-6. (PMID: 11668491)
Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50. (PMID: 18997665)
J Oral Pathol Med. 1994 Sep;23(8):342-6. (PMID: 7815372)
Cancer Res. 2002 Jun 15;62(12):3351-5. (PMID: 12067972)
Science. 1998 Sep 25;281(5385):2042-5. (PMID: 9748166)
Mol Cell Biol. 2006 Nov;26(21):7832-45. (PMID: 16940182)
Oncogene. 2004 Apr 19;23(18):3189-99. (PMID: 15094768)
معلومات مُعتمدة: P30 CA016672 United States CA NCI NIH HHS; P50 CA097007 United States CA NCI NIH HHS; CA016672 United States CA NCI NIH HHS; P50CA097007 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Neoplasm Proteins)
0 (Phosphoproteins)
EC 2.7.11.13 (Protein Kinase C)
تواريخ الأحداث: Date Created: 20110202 Date Completed: 20110523 Latest Revision: 20211020
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3070553
DOI: 10.1016/j.ajpath.2010.10.044
PMID: 21281788
قاعدة البيانات: MEDLINE
الوصف
تدمد:1525-2191
DOI:10.1016/j.ajpath.2010.10.044